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Abstract
Diabetes mellitus and periodontal disease are chronic diseases affecting a large number of populations
worldwide. Changed bone metabolism is one of the important long-term complications associated with
diabetes mellitus. Alveolar bone loss is one of the main outcomes of periodontitis, and diabetes is among
the primary risk factors for periodontal disease. In this review, we summarise the adverse effects of
diabetes on the periodontium in periodontitis subjects, focusing on alveolar bone loss. Bone remodelling
begins with osteoclasts resorbing bone, followed by new bone formation by osteoblasts in the resorption
lacunae. Therefore, we discuss the potential mechanism of diabetes-enhanced bone loss in relation to
osteoblasts and osteoclasts.
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REVIEW

Diabetes mellitus related bone metabolism and
periodontal disease
Ying-Ying Wu1,2, E Xiao2,3 and Dana T Graves2
Diabetes mellitus and periodontal disease are chronic diseases affecting a large number of populations worldwide. Changed bone
metabolism is one of the important long-term complications associated with diabetes mellitus. Alveolar bone loss is one of the main
outcomes of periodontitis, and diabetes is among the primary risk factors for periodontal disease. In this review, we summarise the
adverse effects of diabetes on the periodontium in periodontitis subjects, focusing on alveolar bone loss. Bone remodelling begins with
osteoclasts resorbing bone, followed by new bone formation by osteoblasts in the resorption lacunae. Therefore, we discuss the
potential mechanism of diabetes-enhanced bone loss in relation to osteoblasts and osteoclasts.
International Journal of Oral Science (2015) 7, 63–72; doi:10.1038/ijos.2015.2; published 10 April 2015
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DIABETES: INTRODUCTION
Diabetes mellitus is a heterogeneous group of disorders and is characterized by high blood glucose levels.1 Type 1 diabetes mellitus
(T1DM) results from an absolute deficiency of insulin, which is most
commonly due to auto-immunological destruction of the insulinproducing pancreatic b cells but which can be caused by other etiologies. In type 2 diabetes mellitus (T2DM), muscle, fat and other cells
become resistant to the actions of insulin. This results in the activation
of a compensatory mechanism that induces b cells to secrete more
insulin. T2DM occurs when the compensatory increase in insulin is
insufficient to maintain blood glucose levels within a normal physiological range.2–3 By 2025, 300 million people are projected to be
afflicted with diabetes worldwide, with a prevalence of 6.4%.4–5 The
countries with the most people suffering from diabetes by the year
2025 are predicted to be India, China and the United States. T1DM
represents 5%–10% of the total number of diabetes cases worldwide6
and is the main type of diabetes in youth, representing 85% or more of
all diabetes cases in individuals younger than 20 years of age worldwide.7 On average, males and females are equally affected with T1DM
in young populations.8 T2DM accounts for 90% of diabetes cases
globally.4 This disorder has traditionally been considered a metabolic
disorder of adults; however, it has recently become more common in
young adults, adolescents and occasionally, in children.9
PATHOGENIC MECHANISMS OF DIABETES
T1DM is a polygenic autoimmune disease that is characterized by
the destruction of insulin-secreting pancreatic beta cells.10 T1DM
typically occurs as a consequence of a breakdown in immune regulation, resulting in an expansion of auto-reactive CD41 and CD81 T
cells and auto-antibody-producing B lymphocytes and activation of

the innate immune system, which collaborates to destroy insulinproducing beta cells.11 In an animal model, CD11c1 dendritic cells
and ER-MP231 macrophages are the first cells to infiltrate the pancreas of non-obese diabetic mice, at approximately 3 weeks of age. At
the same time, potentially pathogenic T cells can be detected surrounding the islet, resulting in peri-insulitis.12 Genetic susceptibility
and environmental triggers are thought to contribute to the development of T1DM.13
T2DM is a metabolic disorder that is characterized by hyperglycemia and altered lipid metabolism, which is caused by the inability of
islet b cells to secrete adequate insulin in response to varying degrees of
insulin resistance caused by over-nutrition, inactivity or obesity.
Metabolic defects that contribute to the development of T2DM
include an inability of islet b cells to compensate for high glucose levels
that are associated with excess food intake, increased glucagon secretion and reduced incretin response, impaired expansion of subcutaneous adipose tissue, hypoadiponectinaemia, inflammation of adipose
tissue, increased endogenous glucose production and the development of peripheral insulin resistance.14 Chronic caloric excess is the
primary pathogenic event that drives the development of type 2 diabetes in genetically and epigenetically susceptible individuals.15–16
PATHOGENIC CHANGES IN BOTH T1DM AND T2DM
Hyperglycemia
Hyperglycemia is due to impaired insulin secretion in T1DM and
insulin resistance in T2DM. Beta cell destruction in T1DM and inadequate expression of glucose transporter 2 in T2DM are thought to
contribute to hyperglycemia.17 Several pathways are thought to
exhibit increased activity under hyperglycemic conditions and to contribute to oxidative stress via the polyol pathway,18 the hexosamine
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pathway 19–21 and activator of protein kinase C.22 Hyperglycemia also
leads to greater activation of the pro-inflammatory transcription factor, nuclear factor-kappa B (NF-kB), by protein kinase C in vitro.19
Hyperglycemia also results in the oxidation of sorbitol by NAD1,
thereby increasing the cytosolic NADH:NAD1 ratio and consequently
inhibiting glyceraldehyde-3-phosphate dehydrogenase activation.
Advanced glycation end products
Advanced glycation end products (AGEs) are formed by the nonenzymatic reaction of glucose and other glycating compounds that
are derived from glucose and increased fatty acid oxidation.
Intracellular hyperglycemia is the primary initiating event in the
formation of both intracellular and extracellular AGEs.23 AGEs are
derived from the intracellular auto-oxidation of glucose to glyoxal,24
decomposition of the Amadori product (glucose-derived 1-amino-1deoxyfrutose lysine adducts) and fragmentation of glyceraldehade-3phosphate and dihydroxyacetone phosphate to methylglyoxal.25
These reactive intracellular dicarbonyls (glyoxal, methylglyoxal and
3-deoxyglucosone) react with the amino groups of intracellular and
extracellular proteins to form AGEs. Intracellular proteins that are
modified by AGEs exhibit altered function. Extracellular matrix components that have been modified by AGE precursors interact abnormally with other matrix proteins and their receptors on cells. Several
AGE receptors are linked to increased inflammation, including receptor for AGE (RAGE). Proteins can be structurally modified by glycosylation, thereby affecting their function. Alternatively, AGE binding
to AGE receptors can induce the production of reactive oxygen species, the production of inflammatory cytokines such as tumour necrosis-alpha (TNF-a), and the activation of NF-kB.26
Lipotoxicity
Due to the presence of long-chain free fatty acids in the plasma, lipotoxicity is often increased in states of insulin resistance, thereby
impairing b-cell secretory function 27–28 and contributing to b-cell
apoptosis 29–30 and insulin resistance.31 Muscle cells and hepatocytes
are negatively affected by excessive amounts of fatty acids, which cause
increased ceramide accumulation, activate inflammatory pathways,
and increase the release of reactive oxygen species (ROS) and enhance
apoptosis.32
Oxidative stress
Oxidative stress is central to the development of insulin resistance and
diabetic complications.33–34 Oxidative stress plays a critical role in
diabetic complications. Hyperglycemia leads to the overproduction
of superoxides in mitochondria. This increase in superoxide production activates several pathways that contribute to diabetic complications, including polyol pathway flux, increased AGE formation and
RAGE expression, and activation of protein kinase C and the hexosamine pathway.18 Inflammation induced by increased intracellular
ROS also contributes to diabetic complications.35 After ROS, are created, they deplete cellular antioxidant defences, rendering the affected
cells and tissues more susceptible to oxidative damage.36 It has been
shown that ROS not only play a role in the destruction of cells and
tissues but also function as intracellular second messengers that regulate signal transduction cascades and gene expression. Oxidative stress
can also induce the activation of multiple serine kinases, which impair
the capacity of insulin to stimulate protein kinase B activation and
glucose transport. NF-kB, p38 MAPK and the JNK/SAPK pathway are
sensitive to oxidative stress, which is linked to impaired insulin action
and the development of the late diabetic complications.33
International Journal of Oral Science

Immune response
Neutrophils play a crucial role in several autoimmune diseases, such as
systemic lupus erythematosus and rheumatoid arthritis. Some studies
have noted the involvement of neutrophils in T1DM; a mild neutrophil reduction has been associated with T1DM subjects;37–38 however,
neutrophil counts in T2DM patients are normal.37 The reduction in
circulating neutrophils that is observed in T1DM might be due to
impaired neutrophil differentiation and output from bone marrow,
increased neutrophil apoptosis or anti-neutrophil-specific antibodies,
and increased recruitment into tissues.39 The functional alteration of
mononuclear phagocytes has also been reported in diabetic subjects,
including altered superoxide (O22) production, defective chemotaxis,
and phagocytosis.40 A study has shown that infiltrating monocytes in
T1DM subjects spontaneously secrete pro-inflammatory cytokines,
which are known to induce and expand Th17 cells.41 Evidence also
shows that the classically activated macrophages initiate insulitis and
b-cell death in T1DM subjects and play a role in insulin resistance in
T2DM by triggering an inflammatory response. In contrast, alternatively activated macrophages exert a protective effect in DM by attenuating tissue inflammation.42
Pro-inflammatory factors
Adipose tissue appears to be a major site for inflammatory mediator
production as a result of cross-talk between adipose cells, macrophages,
and other immune cells that infiltrate the expanding adipose tissue.43
Inflammatory mediators might play a dual role in T2DM, contributing
to hyperglycemia-induced insulin resistance and contributing to diabetic complications.44 Pro-inflammatory factors, such as tumor necrosis factor (TNF)-a, interleukin (IL)-1b, IL-6 and IL-18, are reportedly
increased in diabetes mellitus and contribute to insulin resistance by
both JNK and the IKKb/NF-kB pathway.45–46 Enhanced production of
inflammatory cytokines is thought to contribute to insulin resistance
and the destruction of beta cells in the pancreas and is thought to be a
major factor in the development of diabetic complications.47–48
Anti-inflammatory factors
The role of pro-inflammatory cytokines in the destruction of pancreatic b cells and the development of T2DM has been investigated; however, our knowledge about anti-inflammatory proteins is rather
limited, and an imbalance between pro- and anti-inflammatory cytokines might be essential for the development of DM.49–50 IL-1 receptor
antagonist is a naturally occurring anti-inflammatory antagonist of the
IL-1 family of pro-inflammatory cytokines.51 Evidence shows that
blocking IL-1b signals reduces the expression of inflammatory cytokines, and IL-1 receptor antagonist improves glycemic control and
counteracts b-cell destruction.52 Acting as a hormone with anti-inflammatory insulin-sensitizing properties, adiponectin reportedly associates
with a decrease in the risk of T2DM.53 However, increased circulating
levels of adiponectin are found in T1DM patients, this might be
explained by the dependence of T2DM on insulin resistance.50
COMPLICATIONS OF DIABETES
T1DM and T2DM have many possible long-term complications.
Epidemiological studies indicate that the severity of diabetic complications is generally proportional to the degree of hyperglycemia.54
Macrovascular complications
The injurious effects of diabetes on the vascular system are traditionally divided into macrovasular and microvascular complications.55
Evidence suggests that diabetic patients are three times more likely
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to suffer cardiovascular events than are non-diabetic subjects.56
Cardiovascular disease is the most common cause of death in diabetic
patients.57 The central pathological mechanism in macrovascular disease is atherosclerosis. Atherosclerosis is thought to result from
chronic inflammation of the arterial wall in the peripheral or coronary
vascular system. One mechanism is the stimulation of lipid oxidation
of low-density lipoprotein in diabetes mellitus, which accumulates in
the endothelial wall of arteries.
Microvascular complications
High serum glucose levels affect endothelial cells that line blood vessels
and cause the basement membrane to become thicker and less effective.58 Microvascular complications are a significant part of diabetic
retinopathy, nephropathy and neuropathy.59 Diabetes-enhanced TNF
induces the loss of microvascular endothelial cells and pericytes by
activating the transcription factor FOXO1.60–61
Retinopathy
Diabetic retinopathy is clinically classified into non-proliferative and
proliferative disease stages. Only intraretinal microvascular changes
are present in non-proliferative diabetic retinopathy, whereas new
blood vessels are formed on the retina or on the optic disk in proliferative diabetic retinopathy.62 Diabetic retinopathy is characterized by
several common and unique features, including thickening of the
vascular basement membrane, pericyte and endothelial cell death,
microaneurysms, vascular occlusion and pathological neovascularisation, which advance to retinal haemorrhage, retinal detachment, and
vision loss.63 TNF has been shown to play an important role in stimulating the early events of diabetic retinopathy.60
Neuropathy
Diabetic neuropathy is characterized by progressive neuronal loss,
demyelination, and impaired nerve regeneration, with ultimate nerve
fibre dysfunction.62 Diabetic neuropathy can affect sensory, motor and
autonomic nerve fibres in any part of the body.64 Although diabetic
neuropathy has been widely studied for over 20 years, the pathogenesis
of this disease remains unclear; diabetic neuropathy is thought to result
from the diabetic microvascular injury of small blood vessels that supply
nerves, as well as oxidative injury, AGEs and insulin deficiency.65
Nephropathy
Hyperglycemia induces cellular changes in various kidney cell types.
Nephropathy is a progressive kidney disease that is caused by the
angiopathy of capillaries in the kidney glomeruli and is characterized
by glomerular hypertrophy, thickening of basement, tubular and
glomerular membranes and the accumulation of extracellular matrix
in these membranes; these changes finally cause tubulointerstitial and
glomerular fibrosis and sclerosis.66 AGEs, hyperglycemia and vascular
inflammation are thought to cause these pathogenic changes.67–68
DIABETES-RELATED BONE DISEASES
In addition to the complications mentioned above, diabetes affect
bone metabolism. A considerable amount of evidence has accumulated indicating that metabolic and endocrine alterations caused by
diabetes affect bone quantity and quality over the last decades of life.69
Increased fracture risk
T1DM and T2DM are associated with higher fracture risk. A large case
control study in Denmark reported a relative risk for any site fracture
of 1.9.70 The relative risk of hip fracture is estimated as 6.9 in T1DM

patients and as 1.38 in T2DM patients.71 Women with T2DM have a
threefold higher risk of vertebral fracture compared to women who are
non-diabetic.72 In the women’s health initiative study, the risk of
proximal humerus, foot, and ankle fractures was found to be higher
among women with type 2 diabetes than among healthy controls.73
Changed bone mineral density
Bone mineral density (BMD) is reduced in T1DM.72,74 Decreased
BMD and diabetic vascular complications are associated with an
increased risk of fractures. In T2DM, BMD is equal or increased
according a meta-analysis,71 but the fracture risk is increased despite
this increase in BMD.75 The paradoxical increase in fracture rate in
patients with T2DM with increased BMD might result from an
increased rate of falling.76 In addition, decreased bone formation with
decreased bone quality is thought to contribute to a higher fracture risk
in T2DM. Rodent models also support the hypothesis that diabetic
bone has reduced mechanical strength, regardless of bone density.77
Lower bone turnover rate
Decreased bone turnover rate might explain the increased bone fragility in patients with diabetes. Older bone is not replaced by new bone
with decreased bone turnover rate, thus decreasing bone mechanical
strength. This is reflected in studies indicating that diabetic patients
exhibit decreased osteoblast activity.78 Low bone turnover accompanied by reduced mineral content was found in T1DM models.79 Leptin
receptor-deficient mice, a T2DM model, also exhibit decreased bone
turnover.80–81 The impact of diabetes on bone resorption has yielded
contradictory findings, with some studies indicating increased osteoclast activity under perturbation.82–83
Delayed fracture healing
Fracture healing is delayed in diabetic patients. A study of 5 966 cases
of hip fracture in patients with diabetes reported that these patients
required longer in-hospital stays.84 Moreover, diabetic patients undergoing ankle fusing procedures exhibit an increased incidence of nonunion outcomes (from 27% to 38%).85 In diabetic mice that were fed a
high fat diet, fracture calluses were significantly smaller and had markedly increased adiposity.86 In streptozotocin-induced diabetic mice,
fracture calluses exhibited reduced bone formation, which was associated with premature cartilage resorption.87
POTENTIAL MECHANISMS BY WHICH DIABETES
AFFECTS BONE
Bone formation and resorption affect bone, and diabetes mellitus
affects both bone formation and resorption.
Effect of diabetes on osteoblasts
Diabetes has a significant effect on osteoblasts. It has consistently been
noted that diabetes causes a reduction in the number of bone-forming
cells.88 One of the mechanisms through which diabetes affects osteoblasts is increased apoptosis. For example, AGEs induce osteoblast
apoptosis through the MAP kinase pathway.89 Diabetes also interferes
with bone formation by reducing the expression of transcription factors that regulate osteoblast differentiation.90 In rat models of T1DM
and T2DM, osteoblasts exhibit lower alkaline phosphatase activity and
mineralized matrix formation.91–92 When AGEs are applied to
wounds in normal animals, the rate of healing is reduced by half,
suggesting that AGEs, which are present at higher levels in diabetes,
contribute to impaired bone healing.93 In addition, the receptor for
AGEs, RAGE, is expressed at higher levels in osteoblasts in diabetic
International Journal of Oral Science
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conditions, thus rendering diabetic animals even more sensitive to the
effects of AGEs.93
Inflammation also has a significant effect on bone.94 Elevated levels
of inflammatory mediators, particularly TNF, are among the striking
features of diabetes.95 Diabetic animals exhibit higher levels of TNF in
bone, and enhanced TNF levels are associated with reduced bone
healing. Thus, diabetes-enhanced TNF contributes to an increase in
bone cell apoptosis, which reduces osseous healing.96 Moreover, diabetes causes a more than two-fold induction of more than 70 genes
that directly or indirectly regulate apoptosis during inflammationinduced bone injury and that significantly enhance caspase-8, -9 and
-3 activity.97 A significant effect on bone, which was induced by cell
death in diabetic animals, was shown by treating mice with a pancaspase inhibitor. Treatment with this inhibitor increased the number of
bone-lining cells and enhanced new bone formation.97 Profiling of
mRNA expression during diabetic fracture indicates that gene sets that
are related to apoptosis are significantly upregulated.98 The increased
expression of apoptotic genes is associated with elevated TNF-a levels,
increased chondrocyte apoptosis and increased activity of the proapoptotic transcription factor, FOXO1. Inhibition of TNF significantly reduces each of these effects in diabetic fracture healing but
has little effect in normoglycemic mice.98
Mesenchymal stem cells represent a precursor pool of osteoblasts,
which are bone-forming cells. Inflammation, which is elevated in diabetic bone healing,96 has a significant effect on reducing mesenchymal
stem cell (MSC) differentiation.99 Inflammation affects MSC through
the induction of NF-kB activation. Increased NF-kB activity interferes
with wnt-stimulated MSC differentiation by increasing beta-catenin
degradation.100 Moreover, TNF suppresses Osx promoter activation,101 thus interfering with the differentiation of MSCs to osteoblasts
because osterix is required during the early steps of differentiation.
AGEs also inhibit MSC differentiation. One mechanism by which this
occurs involves the upregulation of ROS by AGEs in MSCs, leading to
a decrease in MSC differentiation.102–103 In human mesenchymal stem
cells and mouse stromal ST2 cells, AGEs suppress the osteogenic differentiation of both cell types by increasing TGF-b expression.104 In a
T2DM mouse model, the diabetic mouse has fewer MSCs, and these
MSCs exhibit poor ability to target the injury site.105 In a T1DM rat,
more numerous apoptotic cells were present in hyperglycemic bone
marrow, and the size of the osteoprogenitor pool was significantly
reduced.92 Thus, elevated levels of TNF and the effects of AGEs might
interfere with the production of osteoblasts that are formed by inhibiting the differentiation of MSC to osteoblasts.
Effect of diabetes on osteoclasts
Human studies of diabetes mellitus generally indicate that osteoclastogenesis is enhanced. Humans with T2DM exhibit increased circulating levels of tartrate-resistant acid phosphatase, which is indicative of
increased osteoclast activity.82 In patients with T1DM or T2DM, poor
glycemic control leads to increased bone resorption and bone loss.78 In
patients with T2DM, levels of the bone resorption marker tartrateresistant acid phosphatase are increased in serum, indicating increased
osteoclastic function, which might be due to the diabetic polyol pathway.106 However, some studies indicate that bone resorption markers
are decreased in individuals with T2DM.107
Animal studies generally indicate that osteoclast activity is increased
in diabetic patients.108–109 In streptozotocin-induced T1DM rats,
cathepsin K expression is elevated compared to a control group, indicating increased osteoclast activity.110 In T2DM rats, osteoclastic bone
resorption is enhanced compared to normoglycemic controls.111 In
International Journal of Oral Science

diabetic mice, TNF-a, macrophage-colony stimulating factor, receptor activator of nuclear factor kappa-B ligand (RANKL) and vascular
endothelial growth factor-A are upregulated; this upregulation can
directly promote osteoclast differentiation and activation.87,112
Patients with T2DM exhibit elevated mitochondrial ROS levels, which
promote RANKL-mediated osteoclast differentiation and function.113
Increased fatty acid levels in patients with diabetes mellitus can induce
osteoclastogenesis by TNF-a.114 T2DM mice exhibited enhanced
osteoclast formation in response to M-CSF and RANKL.82 In vitro
studies suggest that hyperglycemia predisposes patients to increased
osteoclast formation.115 AGEs might also increase osteoclast activity.116 Mice that lack the receptor for AGE, RAGE, exhibit increased
bone mass and decreased osteoclast numbers compared to wild-type
mice,117 supporting the concept that AGEs contribute to osteoclast
formation in patients with diabetes.
PERIODONTAL DISEASE: INTRODUCTION
Periodontitis is one of the most widespread oral diseases and is characterized by the loss of connective tissues within the periodontium and
the destruction of alveolar bone support.118–119 Severe periodontitis,
which can result in tooth loss, is found in 5%–20% of most adult
populations worldwide. The latest data from the 2009 and 2010
National Health and Nutrition Examination Survey cycle estimates
that over 47% American adults have had periodontitis.120 An epidemiology study shows that almost 25% of adults in Australia aged 35–54
years have moderate or severe periodontitis, and 34% of 30- to 39year-old adults living in Pomerania have periodontitis.121 Children
and adolescents can have any of the several forms of periodontitis,
such as aggressive periodontitis, chronic periodontitis and periodontitis as a manifestation of systemic diseases.122 However, estimates of
the global prevalence of periodontitis differ based on the distribution
of the disease and the methodologies used to assess it.123
PATHOGENIC MECHANISMS OF PERIODONTAL DISEASE
Microorganisms
The chronic inflammatory condition of periodontitis is induced by
pathogenic biofilms or dental plaque, which accumulates on the tooth
surface. Over 500 bacterial species have been detected in periodontal
plaque; however, the composition of the causative bacterial species is
still under debate.123–126 ‘Red complex’ Gram-negative bacteria, comprising Porphyromonas gingivalis, Tannerella forsythia and Treponema
denticola, have been proposed as the primary aetiological agents of
periodontitis.127 Recent studies have identified Filifactoralocis and
many species of Spirochetes as being closely linked to periodontitis.128
As the best characterized periopathogen, P. gingivalis is a minor constituent of the total microbiota but can trigger changes in the amount
and composition of the oral commensal microbiota that can disrupt
homeostasis and cause inflammatory periodontal bone loss.129 Grampositive bacterial and oral commensal bacteria might also play a significant role in the development of periodontitis 128,130–131.
Modern high-throughput techniques indicate that the subgingival
microbial profiles from periodontitis patients differ according to age,
pocket depth, gender and race.128,132–133 Interestingly, bacteria community diversity has been shown to increase with a history of periodontitis, which runs counter to most bacterial infectious processes,
which are generally associated with decreased diversity.128
Host response
Although bacteria are necessary for periodontal disease to occur, a
susceptible host is also needed.123 The inflammatory process occurring
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in periodontitis is characterized by the infiltration of leukocytes, which
limit the level of bacterial invasion and can be harmful to the periodontal tissue.134 Periodontal ligament and bone destruction is
thought to be caused by a disruption of the homeostatic balance
between the host response and bacteria, which causes inflammation
in close proximity to bone.129,134–135 The process is thought to involve
the host immune response to bacterial infection through the stimulation of osteoclastogenic factor production by immune cells, which
then help to cause the periodontitis-related bone loss. Our laboratory
has recently shown that the production of factors by osteoblasts and
osteocytes also contributes to osteoclast formation and activity in
periodontal disease (unpublished data). Evidence that the host response plays a critical role has also shown by studies in which treatment
with a prostaglandin inhibitor reduced periodontitis-related bone
loss136 and studies involving the inhibition of inflammatory cytokines,
such as IL-1 and TNF.137–138 Thus, periodontitis is a complex disease
in which multiple causal risk factors play simultaneous and interactive
roles; these risk factors include the immune-inflammatory status and
genetic background of individuals, and the presence of environmental
stressors and/or systemic diseases, such as diabetes.139–141
Effects of diabetes on periodontitis
Diabetes and chronic periodontitis are chronic diseases that have long
been considered to be biologically linked.142–143 In fact, diabetes is one
of the primary risk factors for periodontitis.144–145 Cross-sectional and
longitudinal studies identified that the risk of periodontitis is approximately 3–4 times higher in people with diabetes than in non-diabetic
subjects.144 Periodontitis was found in 57.9% of T1DM patients and in
15.0% in controls without diabetes.146 In another study on the periodontal status in children and adolescents with T1DM, a prevalence of
20.8% of gingivitis and 5.9% of periodontitis was observed.147 Patients
with T2DM were also at higher risk of having severe forms of periodontitis compared with non-diabetic subjects.148 A study in African
Americans found that 70.6% of patients with T2DM had moderate
periodontitis, and 28.5% had a severe form of the disease; this value is
significantly higher than the prevalence of 10.6% among control subjects without diabetes.149 A direct relationship exists between the level
of glucose control and the severity of periodontitis.146,150 The odds
ratios of T2DM with periodontal destruction in comparison to nondiabetics are 1.97, 2.10 and 2.42 in well, moderately and poorly controlled diabetics, respectively.151
EFFECTS OF DIABETES ON PERIODONTIUM TISSUES
Gingiva/gingivitis
Periodontitis is preceded by various stages of gingival inflammation,
which are referred to as gingivitis. The prevalence of gingivitis in
children and adolescents with T1DM is nearly twice that observed in
children and adolescents without diabetes.152 Evidence shows that the
gingival index was 1.54 in a 5- to 9-year-old diabetic group and 1.14 in
the control group; however, in the corresponding 10- to 14-year-old
group, the gingival index was 1.98 in diabetic subjects and 1.17 in
control subjects.153 Furthermore, gingival bleeding index is significantly correlated with age and the level of glycosylated haemoglobin.154 Similarly, the rates of gingival inflammation in adults
with T2DM are higher than those in adults without diabetes. Nearly
64% of patients with T2DM have gingivitis; however, only 50% of
subjects without diabetes have the disease.152 The degree of metabolic
control of diabetes is an important factor in the development and
progression of gingivitis; good control significantly reduces the prevalence of gingivitis.155–156 In animal models, diabetes leads to the

increased production of TNF in the epithelium and connective tissue.157 Periodontal infection causes an increase in epithelial cell and
connective tissue fibroblast apoptosis, which is significantly enhanced
by diabetes through a caspase-3-dependent mechanism.157 This is
significant because increased diabetes-enhanced inflammation and
apoptosis are thought to negatively impact the gingiva by causing a loss
of epithelial barrier function and inhibiting repair processes.158–159
Animal studies have demonstrated that high levels of TNF-a can stimulate the expression of pro-apoptotic genes, which induce apoptosis.96,160
In vivo studies have demonstrated that the inhibition of TNF-a reduces
connective tissue cell apoptosis.161
Periodontal ligament/loss of attachment
Periodontitis involves the loss of tooth-supporting structures comprising connective tissue attachment and bone. A statistically significant association is observed between diabetes and loss of attachment,
and the level of glycemic control is an important determinant of this
relationship.146,162 The odds ratio of T1DM patients with attachment
loss is 3.84 compared with non-diabetic subjects.163 In addition, more
than 25% of T1DM patients with poor metabolic control exhibit sites
with clinical attachment loss of o5 mm, compared with 10% of subjects with good metabolic control.152 Subjects with T2DM also exhibit
a significantly higher number of sites with clinical attachment loss of
o3 mm as well as loss of o5 mm. Furthermore, the prevalence of
sites with moderate to severe attachment loss is proportional to the
duration of diabetes.150,164
Alveolar bone/loss of bone
Diabetes potentiates the severity of periodontitis and accelerates bone
resorption. The percentage of sites with bone loss in poorly controlled
T1DM individuals is 44% compared to 28% and 24% in well-controlled and non-diabetic subjects, respectively.165 Animal studies also
demonstrate that alveolar bone loss in rats with STZ-induced T1DM
with periodontitis was threefold higher than in normal rats.166–167 The
risk and degree of alveolar bone loss is positively correlated with lack of
metabolic control.168–169
MECHANISMS OF DIABETES ENHANCED PERIODONTAL
BONE LOSS
The process of bone remodelling starts with the resorption of bone by
osteoclasts, followed by new bone formation by osteoblasts in the
resorption lacunae. Under physiological conditions, these two activities are coupled; however, the two processes are uncoupled in pathological processes.118,134 Diabetes affects osteoclast and osteoblasts in
the periodontium in different ways, such as by increasing the expression of inflammatory mediators and RANKL/osteoprotegerin (OPG)
ratios and by enhancing the levels of AGEs and ROS (Figure 1).
Effect of diabetes on osteoclasts in periodontitis
Diabetes has been shown to enhance osteoclast formation in inflamed
areas. Rats with T2DM exhibit a two- to four-fold increase in osteoclast number after bacterial infection by oral inoculation of a periodontal pathogen ligature that induces periodontitis compared with
control rats.111,157,170 Rats with T1DM and periodontitis also exhibit a
two- to four-fold increase in the number of osteoclasts compared to
non-diabetic rats with periodontitis.171
A higher degree of inflammation and a more persistent inflammatory response following periodontitis are reported in rats with
T1DM and T2DM in response to the same inoculation of periodontal
pathogen.172–173 Diabetes impairs the resolution of periodontal
International Journal of Oral Science
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Diabetes

Increased
RANKL/OPG

Enhanced PDL and
osteoblast apoptosis

Increased AGEs
Reduced bone formed
Increased ROS

Enhanced
osteoclastogenesis

Aveolar bone loss

68

Periodontal disease

Increased inflammation
( TNF,IL-1b,IL-6)

Bacterial products

Host response

Figure 1 A potential mechanism of diabetes-related alveolar bone loss in periodontal disease. Diabetes increases the RANKL/OPG ratios and enhances the
expression level of AGEs, ROS and inflammatory mediators, which induce osteoblast apoptosis and osteoclastogenesis. This cascade of events contributes to both
increased bone resorption and reduced reparative bone formation leading to greater alveolar bone loss in periodontal disease that is caused by bacterial pathogens.
AGE, advanced glycation end product; IL, interleukin; OPG, osteoprotegerin; PDL, periodontal ligament; RANKL, receptor activator of nuclear factor kappa-B ligand;
ROS, reactive oxygen species; TNF, tumor necrosis factor.

inflammation. The importance of resolving inflammation has been
demonstrated by treating animals with periodontitis with resolvins174
or by treatment of diabetic animals with TNF inhibitors.160,170
Diabetes-enhanced TNF has been shown to prevent the downregulation of genes that are associated with host defence, apoptosis, cell
signalling and activity, and coagulation/homeostasis/complement.175
Similarly, patients with periodontitis and diabetes were found to have
significantly higher levels of local inflammatory mediators such as IL1b, TNF-a and prostaglandin E2, which result in more prolonged
osteoclast formation and activity.176 Enhancement of IL-17 and IL23 in periodontitis in subjects with T1DM and overexpression of IL-1b
and IL-6 in patients with T2DM have been reported; and these conditions result in osteoclastogenesis and a prolonged duration of
inflammatory responses.177–178 Patients with T2DM and periodontal
disease exhibit increased levels of TNF-a and IL-6, which are also
associated with increased dyslipidemia and lipid peroxidation.179
These results suggest that there is an important association between
T2DM, dyslipidemia and the severity of the local inflammatory response to bacteria.179
The interaction of RANKL with receptors (RANK) on the surface of
osteoclasts is one of the most potent inducers of osteoclast formation
and activity, and OPG inhibits osteoclast formation binding to RANK
and then blocks the activity of RANKL.169–170,180 A number of studies
focusing on osteoclastogenesis-related factors have reported an elevated
expression of RANKL and TNF in diabetes-associated periodontal tissues.180 Studies with animals suggest that RANK-RANKL/OPG ratios
and the level of other inflammatory cytokines, such as TNF, are critical
mediators of the enhanced osteoclastogenesis in diabetes with periodontal disease.170–171,181 TNF levels and the RANKL/OPG ratio in
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periodontitis sites in humans are negatively influenced by poor glycemic
control in subjects with diabetes.179,182
Diabetes enhances the formation of AGEs in the periodontium and
increases the expression of RAGE.183 Gingiva AGEs are increased in
both T1DM- and T2DM-associated periodontitis; however, there is
evidence that subjects affected with T1DM presented a significantly
higher percentage of AGE-positive cells in the epithelium and fibroblasts than did subjects affected with T2DM.184 Osteoclast-like cells
express RAGE, which serves as a positive factor that regulates osteoclast formation.117 AGE accumulation and the interaction of AGEs
with RAGE may contribute to osteoclastogenesis via an increased
expression of the receptor activator of RANKL and OPG downregulation.185 It has been shown that the AGE-RAGE interaction on monocytes activates transcription factor NF-kB, which alters the phenotype
of monocytes/macrophages and results in the increased production of
pro-inflammatory cytokines.186
ROS are known to be one of causes of diabetes-related periodontitis.
The invading bacteria trigger the release of inflammatory cytokines,
leading to increases in the number and activity of neutrophils, which
release ROS in periodontitis.187 During bone resorbtion, osteoclasts
that contain NADPH-oxidase actively produce superoxide.188
Simultaneously, neutrophils in diabetic patients produce more superoxide than neutrophils from normal subjects.26 The imbalance
between ROS production and antioxidant defences result in increased
oxidative stress.189 In addition, the formation of AGEs also increases
oxidative stress in periodontium tissue. It has been shown that certain
ROS (such as superoxide and hydrogen peroxide) activate osteoclasts
and promote osteoclast formation.190 A related process, lipid peroxidation, is also associated with increased periodontal disease-T2DM
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and a greater inflammatory response in periodontal tissues in
humans.179,191
Effect of diabetes on osteoblasts in periodontitis
Evidence exists that both diabetes and bacterial infection in periodontitis enhance the apoptosis of osteoblastic cells, thereby reducing
osseous coupling.161,192 It is likely that both the innate and adaptive
immune responses that are induced by bacterial infection cause osteoblastic cell loss.96,193 Diabetes also increases the loss of periodontal
ligament (PDL) cells that is induced by periodontal infection by
increasing the apoptosis of these cells.111,194 This loss is significant
because the PDL is a rich source of cells that are capable of differentiating into osteoblasts. Studies in diabetic animals indicate that diabetes causes a more than 2-fold induction of genes that regulate the
apoptosis of osteoblasts and fibroblasts following bacterial infection
and a fivefold increase in osteoblast apoptosis.97,195 The apoptosis of
osteoblasts is a significant component of the failure of diabetic animals
to form new bone after the induction of periodontal disease, as shown
by a significant increase in bone formation when diabetic animals are
treated with a specific blocker of apoptosis following periodontal
infection.161
Diabetes leads to the upregulation of pro-apoptotic factors for
osteoblasts, including advanced TNF-a, AGEs and the formation of
ROS, each of which can contribute to apoptosis.161 Animals with
T1DM and T2DM exhibit higher levels of TNF-a in response to a
bacterial stimulus than normoglycemic controls.170,184 Enhanced
TNF-a levels have been directly linked to cellular changes in diabetes-enhanced periodontitis.196 TNF-a impairs the function of
osteoblasts by blocking the differentiation of osteoblasts when inflammation is thought to be present. Furthermore, TNF-a can induce
apoptosis by binding to TNF receptor-1, which triggers the initial
events in apoptosis.158
It has been shown that increased bacterial infection-induced alveolar bone loss in diabetic subjects is accompanied by the enhanced
expression of RAGE and inflammatory AGEs in gingival tissue.197
AGEs have been shown to interfere with osteoblast differentiation
and to induce the apoptosis of osteoblasts in diabetes via the mitogen-activated protein kinase and cytosolic apoptotic pathway.89
Elevated levels of AGEs are found in the periodontium of diabetics,
and the AGE–RAGE interaction results in an increase in pro-inflammatory cytokine expression and induces osteoblast apoptosis.186,198–199
CML-collagen, an AGE that is found in bone and serum, stimulates the
apoptosis of bone-lining cells in vivo and in various osteoblastic cell
cultures, which is mediated by RAGE.200
ROS production is another mechanism by which diabetes increases
apoptosis. Persistent inflammation and hyperglycemia leads to cellular ROS accumulation, which is linked to diabetic complications.199,201 Moreover, increased oxidative stress in periodontal
tissue has been shown to induce osteoblast apoptosis.202 It has been
demonstrated that ROS causes the activation of caspase-3,203 which
mediates osteoblast apoptosis.
CONCLUSION
In summary, diabetes mellitus and periodontal diseases are closely
associated and exhibit similarities to other chronic diseases. Persistent hyperglycemia leading to exaggerated immune-inflammatory responses that are induced by periodontal pathogens is likely to be
responsible for the greater risk and severity of periodontal disease in
diabetics.134,199 Moreover, severe periodontitis that results in alveolar
bone loss is likely to involve the effect of inflammation on both

osteoclasts and osteoblasts. Diabetes has an important effect on
enhancing osteoclastogenesis and on increasing osteoblast apoptosis.
Interestingly, the effect of diabetes on bone loss and coupled bone
formation is likely to involve the impact of diabetes on both the innate
and adaptive immune responses.47,134
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